Subscribe
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma
Issues
2016
November 2016, Vol 7, No 10
November 2016, Vol 7, No 10
Cabozantinib a New First-Line Standard Therapy for High-Risk Advanced Renal-Cell Carcinoma?
By
Charles Bankhead
Renal-Cell Carcinoma
November 2016, Vol 7, No 10
Copenhagen, Denmark—The current standard for the first-line targeted treatment of metastatic renal-cell carcinoma (RCC) came out on the short end of a randomized comparison with the new multikinase inhibitor cabozantinib (Cabometyx), according to results reported at the 2016 European Society for Medical Oncology Congress.
Read Article
Adjuvant Sunitinib Therapy Improves Outcomes in Clear-Cell Renal-Cell Carcinoma
By
Phoebe Starr
Renal-Cell Carcinoma
November 2016, Vol 7, No 10
Copenhagen, Denmark—For the first time, a randomized clinical trial has shown that adjuvant therapy improves outcomes in patients with clear-cell renal-cell carcinoma (RCC). Adjuvant treatment with sunitinib (Sutent) improved disease-free survival (DFS) by >1 year in patients with high-risk locoregional RCC after nephrectomy, according to results from the S-TRAC clinical trial. Although this is encouraging news, at the 2016 European Society for Medical Oncology Congress some experts noted they were not ready to adopt it as a new standard of care, because of the associated toxicity and lack of an overall survival benefit.
Read Article
Adding Pembrolizumab to Chemotherapy as First-Line Treatment Significantly Improves Outcomes in Patients with Advanced NSCLC
By
Charles Bankhead
Lung Cancer
,
Solid Tumors
November 2016, Vol 7, No 10
Copenhagen, Denmark—Immunotherapy for advanced non–small-cell lung cancer (NSCLC) took a step toward first-line indication as results from a randomized clinical trial showed that patients who received pembrolizumab (Keytruda) plus chemotherapy had a significantly higher response rate compared with patients who received chemotherapy alone, reported Corey J. Langer, MD, Abramson Cancer Center of the University of Pennsylvania, Philadelphia, at the 2016 European Society for Medical Oncology (ESMO) Congress. The clinical trial results (KEYNOTE-021) were also published in
Lancet Oncology
, and are available online.
Read Article
Immunotherapy with Atezolizumab Outperforms Chemotherapy in Previously Treated NSCLC
By
Charles Bankhead
Lung Cancer
,
Solid Tumors
November 2016, Vol 7, No 10
Copenhagen, Denmark—Immunotherapy competition in non–small-cell lung cancer (NSCLC) continued to heat up as atezolizumab (Tecentriq) improved overall survival (OS) versus docetaxel, according to results from the randomized, phase 3 OAK clinical trial reported at the 2016 European Society for Medical Oncology Congress by Fabrice Barlesi, MD, Professor of Medicine, Aix-Marseille University, France.
Read Article
Ceritinib, a Newer ALK Inhibitor, Improves Progression-Free Survival After Crizotinib Failure in NSCLC
By
Charles Bankhead
Lung Cancer
,
Solid Tumors
November 2016, Vol 7, No 10
Copenhagen, Denmark—Patients with heavily pretreated
ALK
mutation and non–small-cell lung cancer (NSCLC) had significant improvement in progression-free survival (PFS) after receiving the next-generation ALK inhibitor ceritinib, according to results from the ASCEND-5 study reported at the 2016 European Society for Medical Oncology Congress by Giorgio Scagliotti, MD, Professor of Respiratory Medicine, University of Torino, Italy.
Read Article
Pembrolizumab Succeeds, Nivolumab Fails, as First-Line Therapy for Advanced NSCLC
By
Phoebe Starr
Lung Cancer
,
Solid Tumors
November 2016, Vol 7, No 10
Copenhagen, Denmark—Patients with non–small-cell lung cancer (NSCLC) who lack targetable
EGFR
or
ALK
mutations typically receive platinum-based doublet chemotherapy as first-line therapy. Two phase 3 clinical trials presented at the 2016 European Society for Medical Oncology (ESMO) Congress compared immunotherapy and platinum-based chemotherapy as first-line treatment for patients with NSCLC. In KEYNOTE-024, pembrolizumab (Keytruda) was superior to chemotherapy in terms of progression-free survival (PFS) and overall survival (OS), whereas in CheckMate-026, nivolumab (Opdivo) failed to improve PFS compared with chemotherapy.
Read Article
Nivolumab Improves Quality of Life versus Chemotherapy in Patients with Head and Neck Cancer
By
Phoebe Starr
November 2016, Vol 7, No 10
Copenhagen, Denmark—In recent years, the personal experience of patients with cancer has been recognized as an important factor in determining the value of a treatment. According to patient-reported outcomes from the CheckMate-141 clinical trial presented at the 2016 European Society for Medical Oncology (ESMO) Congress, patients’ quality of life (QOL) remained stable with the immunotherapy nivolumab (Opdivo), whereas it significantly deteriorated with chemotherapy.
Read Article
Angiogenesis Inhibitor Has Modest Effect on Progression-Free Survival in Metastatic Colorectal Cancer
By
Charles Bankhead
November 2016, Vol 7, No 10
Copenhagen, Denmark—Patients with previously treated metastatic colorectal cancer (mCRC) had a small but significant improvement in progression-free survival (PFS) but no overall survival (OS) benefit after receiving the multikinase inhibitor nintedanib (Ofev), according to results from the LUME-Colon 1 clinical trial reported by principal investigator Eric Van Cutsem, MD, Clinical Digestive Oncology, University Hospitals Leuven, Belgium, at the 2016 European Society for Medical Oncology Congress.
Read Article
Fulvestrant Tops Anastrozole in ER-Positive Breast Cancer
By
Charles Bankhead
November 2016, Vol 7, No 10
Copenhagen, Denmark—A novel approach to targeting the estrogen receptor (ER) led to improved progression-free survival (PFS) in postmenopausal women with advanced, hormone receptor (HR)-positive breast cancer, according to data from the FALCON clinical trial that were reported at the 2016 European Society for Medical Oncology Congress.
Read Article
Adjuvant Ipilimumab Therapy Shows Long-Term Survival Benefit in Patients with High-Risk Melanoma
By
Charles Bankhead
ESMO 2016
,
ESMO
November 2016, Vol 7, No 10
Copenhagen, Denmark—Adjuvant immunotherapy with ipilimumab (Yervoy) led to significant improvement in long-term overall survival (OS) among patients with high-risk melanoma, according to results from a 5.3-year follow-up in a randomized clinical trial reported at the 2016 European Society for Medical Oncology Congress and published simultaneously online.
Read Article
Page 2 of 3
1
2
3
View the Latest Issue of VBCC
Read Issue
Top Trending Articles
1.
Navigating the Complex Landscape of Oral Cancer Medication
2.
Luspatercept Yields Improved Transfusion Independence Compared With Epoetin Alfa in Patients With Lower-Risk MDS
Phoebe Starr
3.
New NCCN Guidelines for CLL/SLL Include Second-Generation BTK Inhibitors
Wayne Kuznar
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma